Apellis Pharmaceuticals, Inc. 8-K

What Happened
Apellis Pharmaceuticals (APLS) announced on April 28, 2026 that its compensation committee approved an amendment and restatement of the Executive Separation Benefits and Retention Plan in connection with the Agreement and Plan of Merger among Apellis, Biogen Inc. and Aspen Purchaser Sub. The amended plan becomes effective on — and only if — the merger Closing Date, and changes how certain equity awards vest and how “Good Reason” is defined for top executives.

Key Details

• Approved by the compensation committee on April 28, 2026; effective only upon the merger Closing Date.
• The amendment accelerates full vesting of participants’ Converted Options and Converted RSU Awards (as defined in the Merger Agreement) if the participant is terminated by Apellis without cause or resigns for good reason before those rights otherwise vest.
• The carve‑out in the plan’s “Good Reason” definition that previously excluded scope changes solely resulting from Apellis becoming a subsidiary will no longer apply to C‑Level Officers (which includes the company’s named executive officers).
• The change affects participants in the Executive Separation Benefits and Retention Plan (including all named executive officers) but does not disclose dollar amounts or report any actual officer departures.

Why It Matters
For investors, this amendment clarifies post‑merger executive protections and retention mechanics: senior executives may receive accelerated vesting of converted stock options and RSUs if involuntarily terminated (other than for cause) or if they resign for good reason, and C‑level officers have broader grounds to claim “Good Reason.” That can influence post‑merger compensation payouts and retention incentives, potentially affecting merger-related compensation expense. The filing does not report any executive resignations or specific payout amounts — it simply amends the plan terms to take effect if the Biogen merger closes.